Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethical Approval
2.2. Patient Recruitment
2.3. Sample Collection
2.4. Enzyme-Linked Immunosorbent Assays for Quantification of Inflammatory Marker Expressions in Plasma
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lang, A.E.; Lozano, A.M. Parkinson’s disease. First of two parts. N. Engl. J. Med. 1998, 339, 1044–1053. [Google Scholar] [CrossRef]
- Dauer, W.; Przedborski, S. Parkinson’s disease: Mechanisms and models. Neuron 2003, 39, 889–909. [Google Scholar] [CrossRef] [Green Version]
- Tremblay, M.E.; Cookson, M.R.; Civiero, L. Glial phagocytic clearance in Parkinson’s disease. Mol. Neurodegener. 2019, 14, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kohl, J. The role of complement in danger sensing and transmission. Immunol. Res. 2006, 34, 157–176. [Google Scholar] [CrossRef]
- Loeffler, D.A.; Camp, D.M.; Conant, S.B. Complement activation in the Parkinson’s disease substantia nigra: An immunocytochemical study. J. Neuroinflamm. 2006, 3, 29. [Google Scholar] [CrossRef] [Green Version]
- Juul-Madsen, K.; Qvist, P.; Bendtsen, K.L.; Langkilde, A.E.; Vestergaard, B.; Howard, K.A.; Dehesa-Etxebeste, M.; Paludan, S.R.; Andersen, G.R.; Jensen, P.H.; et al. Size-Selective Phagocytic Clearance of Fibrillar alpha-Synuclein through Conformational Activation of Complement Receptor 4. J. Immunol. 2020, 204, 1345–1361. [Google Scholar] [CrossRef] [PubMed]
- Navarro-Romero, A.; Montpeyo, M.; Martinez-Vicente, M. The Emerging Role of the Lysosome in Parkinson’s Disease. Cells 2020, 9, 2399. [Google Scholar] [CrossRef]
- Hoenen, C.; Gustin, A.; Birck, C.; Kirchmeyer, M.; Beaume, N.; Felten, P.; Grandbarbe, L.; Heuschling, P.; Heurtaux, T. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant. PLoS ONE 2016, 11, e0162717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siew, J.J.; Chen, H.M.; Chen, H.Y.; Chen, H.L.; Chen, C.M.; Soong, B.W.; Wu, Y.R.; Chang, C.P.; Chan, Y.C.; Lin, C.H.; et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat. Commun. 2019, 10, 3473. [Google Scholar] [CrossRef] [Green Version]
- Gan, P.; Xia, Q.; Hang, G.; Zhou, Y.; Qian, X.; Wang, X.; Ding, L. Knockdown of cathepsin D protects dopaminergic neurons against neuroinflammation-mediated neurotoxicity through inhibition of NF-kappaB signalling pathway in Parkinson’s disease model. Clin. Exp. Pharmacol. Physiol. 2019, 46, 337–349. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.; Sun, Z.; Xiao, S.; Liu, D.; Jin, G.; Wang, E.; Zhou, J.; Zhou, J. Proteomic analysis of the cerebrospinal fluid of Parkinson’s disease patients. Cell Res. 2009, 19, 1401–1403. [Google Scholar] [CrossRef] [Green Version]
- Cengiz, T.; Turkboylari, S.; Gencler, O.S.; Anlar, O. The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression. Clin. Neurol. Neurosurg. 2019, 184, 105373. [Google Scholar] [CrossRef] [PubMed]
- Yazar, H.O.; Yazar, T.; Cihan, M. A preliminary data: Evaluation of serum Galectin-3 levels in patients with Idiopathic Parkinson’s Disease. J. Clin. Neurosci. 2019, 70, 164–168. [Google Scholar] [CrossRef]
- Hughes, A.J.; Daniel, S.E.; Kilford, L.; Lees, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55, 181–184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoehn, M.M.; Yahr, M.D. Parkinsonism: Onset, progression and mortality. Neurology 1967, 17, 427–442. [Google Scholar] [CrossRef] [Green Version]
- Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 2010, 25, 2649–2653. [Google Scholar] [CrossRef]
- D’Agostino, R.B. An omnibus test of normality for moderate and large size samples. Biometrika 1971, 58, 341–348. [Google Scholar] [CrossRef]
- D’Agostino, R.; Pearson, E.S. Tests for departure from normality. Empirical results for the distributions of b2 and √b1. Biometrika 1973, 60, 613–622. [Google Scholar] [CrossRef]
- Jiang, P.; Gan, M.; Yen, S.H.; McLean, P.J.; Dickson, D.W. Impaired endo-lysosomal membrane integrity accelerates the seeding progression of alpha-synuclein aggregates. Sci. Rep. 2017, 7, 7690. [Google Scholar] [CrossRef] [PubMed]
- Yang, R.Y.; Rabinovich, G.A.; Liu, F.T. Galectins: Structure, function and therapeutic potential. Expert Rev. Mol. Med. 2008, 10, e17. [Google Scholar] [CrossRef]
- Boza-Serrano, A.; Yang, Y.; Paulus, A.; Deierborg, T. Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer’s disease mouse model 5xFAD. Sci. Rep. 2018, 8, 1550. [Google Scholar] [CrossRef] [Green Version]
- Thomas, L.; Pasquini, L.A. Galectin-3-mediated glial crosstalk drives oligodendrocyte differentiation and remyelination. Front. Cell Neurosci. 2018, 12, 297. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, G.M.; Baeesa, S.S. Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders. Front. Neurosci. 2018, 12, 430. [Google Scholar] [CrossRef] [Green Version]
- Dunkelberger, J.R.; Song, W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20, 34–50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stevens, B.; Allen, N.J.; Vazquez, L.E.; Howell, G.R.; Christopherson, K.S.; Nouri, N.; Micheva, K.D.; Mehalow, A.K.; Huberman, A.D.; Stafford, B.; et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131, 1164–1178. [Google Scholar] [CrossRef] [Green Version]
- Shi, Q.; Colodner, K.J.; Matousek, S.B.; Merry, K.; Hong, S.; Kenison, J.E.; Frost, J.L.; Le, K.X.; Li, S.; Dodart, J.C.; et al. Complement C3-deficient mice fail to display age-related hippocampal decline. J. Neurosci. 2015, 35, 13029–13042. [Google Scholar] [CrossRef]
- Yamada, T.; McGeer, P.L.; McGeer, E.G. Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins. Acta Neuropathol. 1992, 84, 100–104. [Google Scholar] [CrossRef]
- Iseki, E.; Marui, W.; Akiyama, H.; Ueda, K.; Kosaka, K. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry. Neurosci. Lett. 2000, 286, 69–73. [Google Scholar] [CrossRef]
- Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Munch, A.E.; Chung, W.S.; Peterson, T.C.; et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481–487. [Google Scholar] [CrossRef] [PubMed]
- Yun, S.P.; Kam, T.I.; Panicker, N.; Kim, S.; Oh, Y.; Park, J.S.; Kwon, S.H.; Park, Y.J.; Karuppagounder, S.S.; Park, H.; et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat. Med. 2018, 24, 931–938. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Hancock, A.M.; Bradner, J.; Chung, K.A.; Quinn, J.F.; Peskind, E.R.; Galasko, D.; Jankovic, J.; Zabetian, C.P.; Kim, H.M.; et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am. J. Pathol. 2011, 178, 1509–1516. [Google Scholar] [CrossRef] [PubMed]
- Goldknopf, I.L.; Sheta, E.A.; Bryson, J.; Folsom, B.; Wilson, C.; Duty, J.; Yen, A.A.; Appel, S.H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson’s disease. Biochem. Biophys. Res. Commun. 2006, 342, 1034–1039. [Google Scholar] [CrossRef]
- Sun, C.; Yu, W.; Zhao, Z.; Song, C.; Liu, Y.; Jia, G.; Wang, X.; Liu, Y. Peripheral humoral immune response is associated with the non-motor symptoms of Parkinson’s disease. Front. Neurosci. 2019, 13, 1057. [Google Scholar] [CrossRef] [Green Version]
- Finehout, E.J.; Franck, Z.; Lee, K.H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 2005, 21, 93–101. [Google Scholar] [CrossRef] [Green Version]
- Alberio, T.; Bucci, E.M.; Natale, M.; Bonino, D.; Di Giovanni, M.; Bottacchi, E.; Fasano, M. Parkinson’s disease plasma biomarkers: An automated literature analysis followed by experimental validation. J. Proteom. 2013, 90, 107–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pawlinski, L.; Tobor, E.; Suski, M.; Biela, M.; Polus, A.; Kiec-Wilk, B. Proteomic biomarkers in Gaucher disease. J. Clin. Pathol. 2021, 74, 25–29. [Google Scholar] [CrossRef]
- Sevlever, D.; Jiang, P.; Yen, S.H. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008, 47, 9678–9687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qiao, L.; Hamamichi, S.; Caldwell, K.A.; Caldwell, G.A.; Yacoubian, T.A.; Wilson, S.; Xie, Z.L.; Speake, L.D.; Parks, R.; Crabtree, D.; et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain 2008, 1, 17. [Google Scholar] [CrossRef] [Green Version]
- Parnetti, L.; Paciotti, S.; Eusebi, P.; Dardis, A.; Zampieri, S.; Chiasserini, D.; Tasegian, A.; Tambasco, N.; Bembi, B.; Calabresi, P.; et al. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson’s disease patients. Mov. Disord. 2017, 32, 1423–1431. [Google Scholar] [CrossRef] [PubMed]
NC (n = 46) | PD (n = 56) | |
---|---|---|
Age (years) | 65.91 ± 9.78 | 64.79 ± 10.15 |
Age at onset (years) | 58.75 ± 10.13 | |
Disease duration (years) | 6.04 ± 5.50 | |
Male (%) | 25 (54.34) | 32 (57.14) |
Hoehn and Yahr stage | 2.57 ± 1.13 | |
LEDD (mg) | 757.40 ± 524.01 | |
Dyskinesia (%) | 15 (26.79) | |
HbA1c (%) | 6.51 ± 1.37 | 6.21 ± 0.68 |
Creatinine | 0.78 ± 0.25 | 0.81 ± 0.24 |
AST | 26.66 ± 7.75 | 26.27 ± 12.03 |
ALT | 22.13 ± 10.85 | 17.51 ± 16.02 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wu, H.-C.; Chang, K.-H.; Chiang, M.-C.; Chen, C.-M. Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease. Brain Sci. 2021, 11, 1515. https://doi.org/10.3390/brainsci11111515
Wu H-C, Chang K-H, Chiang M-C, Chen C-M. Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease. Brain Sciences. 2021; 11(11):1515. https://doi.org/10.3390/brainsci11111515
Chicago/Turabian StyleWu, Hsiu-Chuan, Kuo-Hsuan Chang, Mu-Chun Chiang, and Chiung-Mei Chen. 2021. "Alterations of Plasma Galectin-3 and C3 Levels in Patients with Parkinson’s Disease" Brain Sciences 11, no. 11: 1515. https://doi.org/10.3390/brainsci11111515